Cumberland Pharma rises as drug helps treat bacterial infection in COVID-19 patients

Cumberland Pharmaceuticals

21/06/2021 15:53

** Shares of drugmaker Cumberland Pharmaceuticals Inc
 CPIX.O  rise 4.9% to $3.12
    ** Says five case studies show effectiveness of co's Vibativ
drug in treating hospital-acquired and ventilator-associated
bacterial pneumonia in COVID-19 patients  urn:newsml:reuters.com:*:nPn1YdgSYa
    ** Many of the patients had diabetes, heart disease and
other underlying health conditions - CPIX
    ** Vibativ is a U.S. FDA-approved injectable anti-infective
for treatment for certain serious bacterial infections
    ** In 2020, CPIX expanded availability of the drug to treat
hospital-acquired bacterial pneumonia and ventilator-associated
bacterial pneumonia in COVID-19 patients across U.S.

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))